CD19
CD19, also known as B4 or CVID3, is a membrane immunoglobulin that is expressed on follicular dendritic cells and B cells. It contains two Ig-like C2-type domains in the extracellular portion while the cytoplasmic portion undergoes phosphorylation upon the recipient of different cellular signals. CD19 is involved in the B cell response to antigens. It is a low-affinity antigen receptor that is crucial for the decreasing of the threshold for antigen receptor-dependent stimulation. CD19 is often associated with CD21, CD81, CD82, VAVA2, and Complement receptor 2 for its biological function. Defects in CD19 are the main cause of immunodeficiency common variable type 3 (CVID3), or antibody deficiency, a disorder that is characterized by poor B-cell differentiation and impaired antibody production.
CD19 is a biomarker for B-cell lymphomas. It is now under evaluation as a target for antibody-based immunotherapies against B-cell lymphomas as well as some autoimmune diseases.
Entrez Gene ID: 930
UniProt ID: P15391
Catalog | Product name | Similar to | Antibody | Linker | Payload | Data sheet | Inquiry |
ADC-W-093 | Anti-CD22 (hLL2)-SN-38 ADC | Humanized Anti-CD22-antibody, hLL2 | SN-38 (7-ethyl-10-hydroxycamptothecin) | Inquiry | |||
ADC-W-177 | Anti-CD22 (clone 10F4v3)-BMPEO-DM1 ADC | Anti-CD22 antibody, clone # 10F4v3 | BMPEO (bis-maleimido-trioxyethylene glycol) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-180 | Anti-CD22 (clone 5E8)-SMCC-DM1 ADC | Anti-CD22 antibody, clone # 5E8 | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-181 | Anti-CD22 (clone 7A2)-SMCC-DM1 ADC | Anti-CD22 antibody, clone # 7A2 | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-182 | Anti-CD22 (clone 10F4v1)-SMCC-DM1 ADC | Humanized Anti-CD22 antibody, clone # 10F4v1 | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-183 | Anti-CD22 (clone 10F4v2)-SMCC-DM1 ADC | Humanized Anti-CD22 antibody, clone # 10F4v2 | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-184 | Anti-CD22 (clone 10F4v2)-Mc-MMAF ADC | Humanized Anti-CD22 antibody, clone # 10F4v2 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) | Inquiry | ||
ADC-W-185 | Anti-CD22 (clone 10F4v3)-SMCC-DM1 ADC | Humanized Anti-CD22 antibody, clone # 10F4v3 | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-186 | Anti-CD22 (clone 10F4v3)-Mc-MMAF ADC | Humanized Anti-CD22 antibody, clone # 10F4v3 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) | Inquiry | ||
ADC-W-187 | Anti-CD22 (clone 10F4v3)-SPP-DM1 ADC | Humanized Anti-CD22 antibody, clone # 10F4v3 | SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-188 | Anti-CD22 (clone 10F4v3)-Mc-VC-PABC-MMAE ADC | Humanized Anti-CD22 antibody, clone # 10F4v3 | MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE (Monomethyl auristatin E) | Inquiry | ||
ADC-W-189 | Anti-CD22 (clone 10F4)-SMCC-DM1 ADC | Anti-CD22 antibody, clone # 10F4 | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-190 | Anti-CD22 (clone RFB4)-SMCC-DM1 ADC | Anti-CD22 antibody, clone # RFB4 | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-191 | Anti-CD22 (clone RFB4)-Mc-VC-PABC-MMAF ADC | Anti-CD22 antibody, clone # RFB4 | MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAF (Monomethyl auristatin F) | Inquiry | ||
ADC-W-192 | Anti-CD22 (clone RFB4)-Mc-MMAF ADC | Anti-CD22 antibody, clone # RFB4 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) | Inquiry | ||
ADC-W-193 | Anti-CD22 (clone RFB4)-Mc-VC-PABC-MMAE ADC | Anti-CD22 antibody, clone # RFB4 | MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE (Monomethyl auristatin E) | Inquiry | ||
ADC-W-195 | Anti-CD22 (clone 10F4v1)-Mc-MMAF ADC | Anti-CD22 antibody, clone # 10F4v1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) | Inquiry | ||
ADC-W-216 | Anti-CD22 (10F4v3)-Mc-VC-PABC-MMAE ADC | Humanized Anti-CD22 lgG1 Antibody, 10F4v3 | MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE (Monomethyl auristatin E) | Inquiry | ||
ADC-W-217 | Anti-CD22 (10F4v3)-Mc-MMAF ADC | Humanized Anti-CD22 lgG1 Antibody, 10F4v3 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) | Inquiry | ||
ADC-W-331 | Anti-CD22 (clone RFB4)-MCC-DM1 ADC | Chimeric Anti-CD22 Antibody, clone # RFB4 | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-332 | Anti-CD22 (clone 10F4)-AcBut-Calicheamicin ADC | Humanized Anti-CD22 Antibody | AcBut [-(4' acetyl phenoxy) butanoic acid] | calicheamicin | Inquiry | ||
ADC-W-335 | Anti-CD22-Mc-MMAF ADC | Humanized Anti-CD22 Antibody | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) | Inquiry | ||
ADC-W-336 | Anti-CD22-MCC-DM1 ADC | Humanized Anti-CD22 Antibody | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-337 | Anti-CD22 (Pinatuzumab)-Mc-VC-PABC-MMAE ADC | Humanized Anti-CD22 Antibody, Pinatuzumab | MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE (Monomethyl auristatin E) | Inquiry | ||
ADC-W-338 | Anti-CD22 (Inotuzumab)-hydrazone-Calicheamicin ADC | Humanized Anti-CD22 Antibody, Inotuzumab | hydrazone | calicheamicin | Inquiry | ||
ADC-W-339 | Anti-CD22-DIBO-doxorubicin ADC | Humanized Anti-CD22 Antibody, Inotuzumab | DIBO (dibenzylcyclooctynol) | doxorubicin | Inquiry | ||
ADC-W-461 | Anti-CD22 (clone G5/44)-AcBut-CalichDMH ADC | inotuzumab ozogamicin | Humanized Anti-CD22 Antibody, clone # G5/44 | AcBut (4-(4-acetylphenoxy)butanoic acid) | CalichDMH | Inquiry | |
ADC-W-484 | Anti-CD22 (clone hu10F4)-MCC-DM1 ADC | hu10F4-MCC-DM1 | Humanized Anti-CD22 Antibody, hu10F4 | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | |
ADC-W-540 | Anti-CD22-Mc-VC-PAB-NMS249 ADC | Anti-CD22 Antibody | mc-VC-PAB (proteaselabile maleimido-caproyl-valine-citrulline-para-amino-benzyloxy carbonyl ) | NMS249 | Inquiry | ||
ADC-W-586 | Anti-CD22 (clone HB22.7)-saporin ADC | Anti-CD22 Antibody, clone # HB227 | saporin | Inquiry | |||
ADC-W-625 | Anti-CD22 (10F4v3)-SPP-DM1 ADC | Humanized Anti-CD22 lgG1 Antibody, 10F4v3 | SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-626 | Anti-CD22 (10F4v3)-MCC-DM1 ADC | Humanized Anti-CD22 lgG1 Antibody, 10F4v3 | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-794 | Anti-CD22 (Bectumomab)-SMCC-DM1 ADC | Anti-CD22 IgG2a-Fab’ fragment , Bectumomab | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-795 | Anti-CD22 (Bectumomab)-SPDB-DM4 ADC | Anti-CD22 IgG2a-Fab’ fragment , Bectumomab | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) | Inquiry | ||
ADC-W-796 | Anti-CD22 (Bectumomab)-MC-MMAF ADC | Anti-CD22 IgG2a-Fab’ fragment , Bectumomab | MC (maleimidocaproyl) | MMAF | Inquiry | ||
ADC-W-797 | Anti-CD22 (Bectumomab)-MC-Vc-PAB-MMAE ADC | Anti-CD22 IgG2a-Fab’ fragment , Bectumomab | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE | Inquiry | ||
ADC-W-798 | Anti-CD22 (Bectumomab)-MC-Vc-PAB-SN38 ADC | Anti-CD22 IgG2a-Fab’ fragment , Bectumomab | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) | Inquiry | ||
ADC-W-799 | Anti-CD22 (Bectumomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | Anti-CD22 IgG2a-Fab’ fragment , Bectumomab | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA | Inquiry | ||
ADC-W-800 | Anti-CD22 (Moxetumomab pasudotox)-SMCC-DM1 ADC | Anti-CD22 Fv-disulfide stabilized antibody, Moxetumomab pasudotox | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-801 | Anti-CD22 (Moxetumomab pasudotox)-SPDB-DM4 ADC | Anti-CD22 Fv-disulfide stabilized antibody, Moxetumomab pasudotox | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) | Inquiry | ||
ADC-W-802 | Anti-CD22 (Moxetumomab pasudotox)-MC-MMAF ADC | Anti-CD22 Fv-disulfide stabilized antibody, Moxetumomab pasudotox | MC (maleimidocaproyl) | MMAF | Inquiry | ||
ADC-W-803 | Anti-CD22 (Moxetumomab pasudotox)-MC-Vc-PAB-MMAE ADC | Anti-CD22 Fv-disulfide stabilized antibody, Moxetumomab pasudotox | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE | Inquiry | ||
ADC-W-804 | Anti-CD22 (Moxetumomab pasudotox)-MC-Vc-PAB-SN38 ADC | Anti-CD22 Fv-disulfide stabilized antibody, Moxetumomab pasudotox | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) | Inquiry | ||
ADC-W-805 | Anti-CD22 (Moxetumomab pasudotox)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | Anti-CD22 Fv-disulfide stabilized antibody, Moxetumomab pasudotox | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA | Inquiry | ||
ADC-W-2521 | Anti-CD22 (Inotuzumab)-SMCC-DM1 ADC | Humanized Anti-CD22 IgG4-kappa antibody, Inotuzumab | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-2522 | Anti-CD22 (Inotuzumab)-SPDB-DM4 ADC | Humanized Anti-CD22 IgG4-kappa antibody, Inotuzumab | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) | Inquiry | ||
ADC-W-2523 | Anti-CD22 (Inotuzumab)-MC-MMAF ADC | Humanized Anti-CD22 IgG4-kappa antibody, Inotuzumab | MC (maleimidocaproyl) | MMAF | Inquiry | ||
ADC-W-2524 | Anti-CD22 (Inotuzumab)-MC-Vc-PAB-MMAE ADC | Humanized Anti-CD22 IgG4-kappa antibody, Inotuzumab | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE | Inquiry | ||
ADC-W-2525 | Anti-CD22 (Inotuzumab)-MC-Vc-PAB-SN38 ADC | Humanized Anti-CD22 IgG4-kappa antibody, Inotuzumab | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) | Inquiry | ||
ADC-W-2526 | Anti-CD22 (Inotuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | Humanized Anti-CD22 IgG4-kappa antibody, Inotuzumab | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA | Inquiry | ||
ADC-W-2527 | Anti-CD22-SMCC-DM1 ADC | Humanized Anti-CD22 IgG1 antibody | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-2528 | Anti-CD22-SPDB-DM4 ADC | Humanized Anti-CD22 IgG1 antibody | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) | Inquiry | ||
ADC-W-2529 | Anti-CD22-MC-Vc-PAB-MMAE ADC | Humanized Anti-CD22 IgG1 antibody | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE | Inquiry | ||
ADC-W-2530 | Anti-CD22-MC-Vc-PAB-SN38 ADC | Humanized Anti-CD22 IgG1 antibody | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) | Inquiry | ||
ADC-W-2531 | Anti-CD22-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | Humanized Anti-CD22 IgG1 antibody | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA | Inquiry | ||
ADC-W-2532 | Anti-CD22 (Pinatuzumab)-SMCC-DM1 ADC | Humanized Anti-CD22 IgG1-kappa antibody, Pinatuzumab | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-2533 | Anti-CD22 (Pinatuzumab)-SPDB-DM4 ADC | Humanized Anti-CD22 IgG1-kappa antibody, Pinatuzumab | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) | Inquiry | ||
ADC-W-2534 | Anti-CD22 (Pinatuzumab)-MC-MMAF ADC | Humanized Anti-CD22 IgG1-kappa antibody, Pinatuzumab | MC (maleimidocaproyl) | MMAF | Inquiry | ||
ADC-W-2535 | Anti-CD22 (Pinatuzumab)-MC-Vc-PAB-SN38 ADC | Humanized Anti-CD22 IgG1-kappa antibody, Pinatuzumab | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) | Inquiry | ||
ADC-W-2536 | Anti-CD22 (Pinatuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | Humanized Anti-CD22 IgG1-kappa antibody, Pinatuzumab | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA | Inquiry |
If you can’t find your product on this list? Please directly send email to info@creative-biolabs.com
For Research Use Only. NOT FOR CLINICAL USE.
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.